Reprogramming of Cellular Metabolism and Its Therapeutic Applications in Thyroid Cancer
Abstract
:1. Introduction
2. Glucose Metabolism
2.1. Physiology
2.2. Glucose Metabolism Reprogramming in Thyroid Cancers
3. Amino Acid Metabolism
3.1. The Contents of Intracellular Amino Acids and Amino Acid Transporters
3.2. The SSP and One-Carbon Metabolism
3.3. Glutamine Metabolism
4. Lipid Metabolism
4.1. Physiology
4.2. Lipid Metabolism Reprogramming in Thyroid Cancers
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Jung, C.K.; Bychkov, A.; Kakudo, K. Update from the 2022 World Health Organization Classification of Thyroid Tumors: A Standardized Diagnostic Approach. Endocrinol. Metab. 2022, 37, 703–718. [Google Scholar] [CrossRef] [PubMed]
- The Cancer Genome Atlas Research, N. Integrated genomic characterization of papillary thyroid carcinoma. Cell 2014, 159, 676–690. [Google Scholar] [CrossRef] [Green Version]
- Máximo, V.; Lima, J.; Prazeres, H.; Soares, P.; Sobrinho-Simões, M. The biology and the genetics of Hürthle cell tumors of the thyroid. Endocr. Realat. Cancer 2016, 23, X2. [Google Scholar] [CrossRef] [Green Version]
- Asa, S.L.; Mete, O. Oncocytic change in thyroid pathology. Front. Endocrinol. 2021, 12, 678119. [Google Scholar] [CrossRef]
- McFadden, D.G.; Sadow, P.M. Genetics, diagnosis, and management of Hürthle cell thyroid neoplasms. Front. Endocrinol. 2021, 12, 696386. [Google Scholar] [CrossRef]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [Green Version]
- Warburg, O. On the origin of cancer cells. Science 1956, 123, 309–314. [Google Scholar] [CrossRef]
- Yu, S.; Liu, C.; Hou, Y.; Li, J.; Guo, Z.; Chen, X.; Zhang, L.; Peng, S.; Hong, S.; Xu, L.; et al. Integrative metabolomic characterization identifies plasma metabolomic signature in the diagnosis of papillary thyroid cancer. Oncogene 2022, 41, 2422–2430. [Google Scholar] [CrossRef]
- Khatami, F.; Payab, M.; Sarvari, M.; Gilany, K.; Larijani, B.; Arjmand, B.; Tavangar, S.M. Oncometabolites as biomarkers in thyroid cancer: A systematic review. Cancer Manag. Res. 2019, 11, 1829–1841. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Seyfried, T.N.; Arismendi-Morillo, G.; Mukherjee, P.; Chinopoulos, C. On the origin of ATP synthesis in cancer. iScience 2020, 23, 101761. [Google Scholar] [CrossRef] [PubMed]
- Tretter, L.; Patocs, A.; Chinopoulos, C. Succinate, an intermediate in metabolism, signal transduction, ROS, hypoxia, and tumorigenesis. Biochim. Biophys. Acta 2016, 1857, 1086–1101. [Google Scholar] [CrossRef]
- Chiaradonna, F.; Ricciardiello, F.; Palorini, R. The nutrient-sensing hexosamine biosynthetic pathway as the hub of cancer metabolic rewiring. Cells 2018, 7, 53. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Owen, O.E.; Kalhan, S.C.; Hanson, R.W. The key role of anaplerosis and cataplerosis for citric acid cycle function. J. Biol. Chem. 2002, 277, 30409–30412. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009, 324, 1029–1033. [Google Scholar] [CrossRef] [Green Version]
- Gatenby, R.A.; Gillies, R.J. Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 2004, 4, 891–899. [Google Scholar] [CrossRef] [PubMed]
- Hirschhaeuser, F.; Sattler, U.G.; Mueller-Klieser, W. Lactate: A metabolic key player in cancer. Cancer Res. 2011, 71, 6921–6925. [Google Scholar] [CrossRef] [Green Version]
- Zheng, J. Energy metabolism of cancer: Glycolysis versus oxidative phosphorylation (Review). Oncol. Lett. 2012, 4, 1151–1157. [Google Scholar] [CrossRef] [Green Version]
- Calabrese, C.; Iommarini, L.; Kurelac, I.; Calvaruso, M.A.; Capristo, M.; Lollini, P.L.; Nanni, P.; Bergamini, C.; Nicoletti, G.; Giovanni, C.D.; et al. Respiratory complex I is essential to induce a Warburg profile in mitochondria-defective tumor cells. Cancer Metab. 2013, 1, 11. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tian, Y.; Nie, X.; Xu, S.; Li, Y.; Huang, T.; Tang, H.; Wang, Y. Integrative metabonomics as potential method for diagnosis of thyroid malignancy. Sci. Rep. 2015, 5, 14869. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Deja, S.; Dawiskiba, T.; Balcerzak, W.; Orczyk-Pawiłowicz, M.; Głód, M.; Pawełka, D.; Młynarz, P. Follicular adenomas exhibit a unique metabolic profile. ¹H NMR studies of thyroid lesions. PLoS ONE 2013, 8, e84637. [Google Scholar] [CrossRef]
- Xu, Y.; Zheng, X.; Qiu, Y.; Jia, W.; Wang, J.; Yin, S. Distinct metabolomic profiles of papillary thyroid carcinoma and benign thyroid adenoma. J. Proteome Res. 2015, 14, 3315–3321. [Google Scholar] [CrossRef]
- Ryoo, I.; Kwon, H.; Kim, S.C.; Jung, S.C.; Yeom, J.A.; Shin, H.S.; Cho, H.R.; Yun, T.J.; Choi, S.H.; Sohn, C.H.; et al. Metabolomic analysis of percutaneous fine-needle aspiration specimens of thyroid nodules: Potential application for the preoperative diagnosis of thyroid cancer. Sci. Rep. 2016, 6, 30075. [Google Scholar] [CrossRef] [Green Version]
- Li, Y.; Chen, M.; Liu, C.; Xia, Y.; Xu, B.; Hu, Y.; Chen, T.; Shen, M.; Tang, W. Metabolic changes associated with papillary thyroid carcinoma: A nuclear magnetic resonance-based metabolomics study. Int. J. Mol. Med. 2018, 41, 3006–3014. [Google Scholar] [CrossRef]
- Wojakowska, A.; Chekan, M.; Marczak, Ł.; Polanski, K.; Lange, D.; Pietrowska, M.; Widlak, P. Detection of metabolites discriminating subtypes of thyroid cancer: Molecular profiling of FFPE samples using the GC/MS approach. Mol. Cell. Endcrinol. 2015, 417, 149–157. [Google Scholar] [CrossRef]
- Lu, J.; Hu, S.; Miccoli, P.; Zeng, Q.; Liu, S.; Ran, L.; Hu, C. Non-invasive diagnosis of papillary thyroid microcarcinoma: A NMR-based metabolomics approach. Oncotarget 2016, 7, 81768–81777. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Haber, R.S.; Weiser, K.R.; Pritsker, A.; Reder, I.; Burstein, D.E. GLUT1 glucose transporter expression in benign and malignant thyroid nodules. Thyroid 1997, 7, 363–367. [Google Scholar] [CrossRef] [PubMed]
- Strickaert, A.; Corbet, C.; Spinette, S.A.; Craciun, L.; Dom, G.; Andry, G.; Larsimont, D.; Wattiez, R.; Dumont, J.E.; Feron, O.; et al. Reprogramming of energy metabolism: Increased expression and roles of pyruvate carboxylase in papillary thyroid cancer. Thyroid 2019, 29, 845–857. [Google Scholar] [CrossRef] [PubMed]
- Li, Q.; Xu, B.; Tang, Y.; Li, Y.; Ying, H. Effect of monocarboxylate transporter-1 on the biological behavior of iodine-refractory thyroid carcinoma. Transl. Cancer Res. 2021, 10, 4914–4928. [Google Scholar] [CrossRef]
- Gao, Y.; Yang, F.; Yang, X.A.; Zhang, L.; Yu, H.; Cheng, X.; Xu, S.; Pan, J.; Wang, K.; Li, P. Mitochondrial metabolism is inhibited by the HIF1α-MYC-PGC-1β axis in BRAF V600E thyroid cancer. FEBS J. 2019, 286, 1420–1436. [Google Scholar] [CrossRef] [PubMed]
- Huang, P.; Mao, L.F.; Zhang, Z.P.; Lv, W.W.; Feng, X.P.; Liao, H.J.; Dong, C.; Kaluba, B.; Tang, X.F.; Chang, S. Down-regulated miR-125a-5p promotes the reprogramming of glucose metabolism and cell malignancy by increasing levels of CD147 in thyroid cancer. Thyroid 2018, 28, 613–623. [Google Scholar] [CrossRef]
- Hou, X.; Shi, X.; Zhang, W.; Li, D.; Hu, L.; Yang, J.; Zhao, J.; Wei, S.; Wei, X.; Ruan, X.; et al. LDHA induces EMT gene transcription and regulates autophagy to promote the metastasis and tumorigenesis of papillary thyroid carcinoma. Cell Death Dis. 2021, 12, 347. [Google Scholar] [CrossRef] [PubMed]
- Hsu, Y.C.; Liu, C.L.; Yang, P.S.; Tsai, C.H.; Lee, J.J.; Cheng, S.P. Interaction of age at diagnosis with transcriptional profiling in papillary thyroid cancer. World J. Surg. 2016, 40, 2922–2929. [Google Scholar] [CrossRef]
- Wen, S.S.; Zhang, T.T.; Xue, D.X.; Wu, W.L.; Wang, Y.L.; Wang, Y.; Ji, Q.H.; Zhu, Y.X.; Qu, N.; Shi, R.L. Metabolic reprogramming and its clinical application in thyroid cancer. Oncol. Lett. 2019, 18, 1579–1584. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Coelho, R.G.; Fortunato, R.S.; Carvalho, D.P. Metabolic reprogramming in thyroid carcinoma. Front. Oncol. 2018, 8, 82. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Nahm, J.H.; Kim, H.M.; Koo, J.S. Glycolysis-related protein expression in thyroid cancer. Tumour Biol. 2017, 39, 1010428317695922. [Google Scholar] [CrossRef] [Green Version]
- Xu, F.; Xu, H.; Li, Z.; Huang, Y.; Huang, X.; Li, Y.; Zheng, X.; Chen, Y.; Lin, L. Glycolysis-based genes are potential biomarkers in thyroid cancer. Front. Oncol. 2021, 11, 534838. [Google Scholar] [CrossRef]
- Kim, S.; Chung, J.K.; Min, H.S.; Kang, J.H.; Park, D.J.; Jeong, J.M.; Lee, D.S.; Park, S.H.; Cho, B.Y.; Lee, S.; et al. Expression patterns of glucose transporter-1 gene and thyroid specific genes in human papillary thyroid carcinoma. Nucl. Med. Mol. Imaging 2014, 48, 91–97. [Google Scholar] [CrossRef] [Green Version]
- Grabellus, F.; Nagarajah, J.; Bockisch, A.; Schmid, K.W.; Sheu, S.Y. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma. Clin. Nucl. Med. 2012, 37, 121–127. [Google Scholar] [CrossRef]
- Manohar, P.M.; Beesley, L.J.; Bellile, E.L.; Worden, F.P.; Avram, A.M. Prognostic value of FDG-PET/CT metabolic parameters in metastatic radioiodine-refractory differentiated thyroid cancer. Clin. Nucl. Med. 2018, 43, 641–647. [Google Scholar] [CrossRef]
- Feng, C.; Gao, Y.; Wang, C.; Yu, X.; Zhang, W.; Guan, H.; Shan, Z.; Teng, W. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 2013, 98, E1524–E1533. [Google Scholar] [CrossRef]
- Kachel, P.; Trojanowicz, B.; Sekulla, C.; Prenzel, H.; Dralle, H.; Hoang-Vu, C. Phosphorylation of pyruvate kinase M2 and lactate dehydrogenase A by fibroblast growth factor receptor 1 in benign and malignant thyroid tissue. BMC Cancer 2015, 15, 140. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yu, G.; Sun, W.; Shen, Y.; Hu, Y.; Liu, H.; Li, W.; Wang, Y. PKM2 functions as a potential oncogene and is a crucial target of miR-148a and miR-326 in thyroid tumorigenesis. Am. J. Transl. Res. 2018, 10, 1793–1801. [Google Scholar]
- Chen, Y.; Maniakas, A.; Tan, L.; Cui, M.; Le, X.; Niedzielski, J.S.; Michel, K.A.; Harlan, C.J.; Lu, W.; Henderson, Y.C.; et al. Development of a rational strategy for integration of lactate dehydrogenase A suppression into therapeutic algorithms for head and neck cancer. Br. J. Cancer 2021, 124, 1670–1679. [Google Scholar] [CrossRef]
- Nagarajah, J.; Ho, A.L.; Tuttle, R.M.; Weber, W.A.; Grewal, R.K. Correlation of BRAFV600E mutation and glucose metabolism in thyroid cancer patients: An ¹⁸F-FDG PET study. J. Nucl. Med. 2015, 56, 662–667. [Google Scholar] [CrossRef] [Green Version]
- Grabellus, F.; Worm, K.; Schmid, K.W.; Sheu, S.Y. The BRAF V600E mutation in papillary thyroid carcinoma is associated with glucose transporter 1 overexpression. Thyroid 2012, 22, 377–382. [Google Scholar] [CrossRef] [PubMed]
- Yoon, M.; Jung, S.J.; Kim, T.H.; Ha, T.K.; Urm, S.H.; Park, J.S.; Lee, S.M.; Bae, S.K. Relationships between transporter expression and the status of BRAF V600E mutation and F-18 FDG uptake in papillary thyroid carcinomas. Endocr. Res. 2016, 41, 64–69. [Google Scholar] [CrossRef]
- Suh, S.; Kim, Y.H.; Goh, T.S.; Jeong, D.C.; Lee, C.S.; Jang, J.Y.; Cha, W.; Han, M.E.; Kim, S.J.; Kim, I.J.; et al. mRNA expression of SLC5A5 and SLC2A family genes in papillary thyroid cancer: An analysis of the cancer genome atlas. Yonsei Med. J. 2018, 59, 746–753. [Google Scholar] [CrossRef] [PubMed]
- Chen, M.; Shen, M.; Li, Y.; Liu, C.; Zhou, K.; Hu, W.; Xu, B.; Xia, Y.; Tang, W. GC-MS-based metabolomic analysis of human papillary thyroid carcinoma tissue. Int. J. Mol. Med. 2015, 36, 1607–1614. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Liu, C.L.; Hsu, Y.C.; Lee, J.J.; Chen, M.J.; Lin, C.H.; Huang, S.Y.; Cheng, S.P. Targeting the pentose phosphate pathway increases reactive oxygen species and induces apoptosis in thyroid cancer cells. Mol. Cell. Endocrinol. 2020, 499, 110595. [Google Scholar] [CrossRef]
- Giusti, L.; Iacconi, P.; Ciregia, F.; Giannaccini, G.; Donatini, G.L.; Basolo, F.; Miccoli, P.; Pinchera, A.; Lucacchini, A. Fine-needle aspiration of thyroid nodules: Proteomic analysis to identify cancer biomarkers. J. Proteome Res. 2008, 7, 4079–4088. [Google Scholar] [CrossRef]
- Sandulache, V.C.; Skinner, H.D.; Wang, Y.; Chen, Y.; Dodge, C.T.; Ow, T.J.; Bankson, J.A.; Myers, J.N.; Lai, S.Y. Glycolytic inhibition alters anaplastic thyroid carcinoma tumor metabolism and improves response to conventional chemotherapy and radiation. Mol. Cancer Ther. 2012, 11, 1373–1380. [Google Scholar] [CrossRef] [PubMed]
- Coelho, R.G.; Cazarin, J.M.; Cavalcanti de Albuquerque, J.P.; de Andrade, B.M.; Carvalho, D.P. Differential glycolytic profile and Warburg effect in papillary thyroid carcinoma cell lines. Oncol. Rep. 2016, 36, 3673–3681. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lee, J.; Seol, M.Y.; Jeong, S.; Lee, C.R.; Ku, C.R.; Kang, S.W.; Jeong, J.J.; Shin, D.Y.; Nam, K.H.; Lee, E.J.; et al. A metabolic phenotype based on mitochondrial ribosomal protein expression as a predictor of lymph node metastasis in papillary thyroid carcinoma. Medicine 2015, 94, e380. [Google Scholar] [CrossRef] [PubMed]
- Wagner, M.; Wuest, M.; Lopez-Campistrous, A.; Glubrecht, D.; Dufour, J.; Jans, H.S.; Wuest, F.; McMullen, T.P.W. Tyrosine kinase inhibitor therapy and metabolic remodelling in papillary thyroid cancer. Endocr. Relat. Cancer 2020, 27, 495–507. [Google Scholar] [CrossRef]
- Luo, W.; Semenza, G.L. Emerging roles of PKM2 in cell metabolism and cancer progression. Trends Endocrinol. Metab. TEM 2012, 23, 560–566. [Google Scholar] [CrossRef] [Green Version]
- Liu, C.; Zhou, X.; Pan, Y.; Liu, Y.; Zhang, Y. Pyruvate carboxylase promotes thyroid cancer aggressiveness through fatty acid synthesis. BMC Cancer 2021, 21, 722. [Google Scholar] [CrossRef]
- Wang, S.Y.; Wei, Y.H.; Shieh, D.B.; Lin, L.L.; Cheng, S.P.; Wang, P.W.; Chuang, J.H. 2-deoxy-d-glucose can complement doxorubicin and sorafenib to suppress the growth of papillary thyroid carcinoma cells. PLoS ONE 2015, 10, e0130959. [Google Scholar] [CrossRef]
- Lee, M.H.; Lee, S.E.; Kim, D.W.; Ryu, M.J.; Kim, S.J.; Kim, S.J.; Kim, Y.K.; Park, J.H.; Kweon, G.R.; Kim, J.M.; et al. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: A clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. J. Clin. Endocrinol. Metab. 2011, 96, E19–E30. [Google Scholar] [CrossRef] [Green Version]
- Morani, F.; Phadngam, S.; Follo, C.; Titone, R.; Aimaretti, G.; Galetto, A.; Alabiso, O.; Isidoro, C. PTEN regulates plasma membrane expression of glucose transporter 1 and glucose uptake in thyroid cancer cells. J. Mol. Endocrinol. 2014, 53, 247–258. [Google Scholar] [CrossRef] [Green Version]
- Morani, F.; Phadngam, S.; Follo, C.; Titone, R.; Thongrakard, V.; Galetto, A.; Alabiso, O.; Isidoro, C. PTEN deficiency and mutant p53 confer glucose-addiction to thyroid cancer cells: Impact of glucose depletion on cell proliferation, cell survival, autophagy and cell migration. Genes Cancer 2014, 5, 226–239. [Google Scholar] [CrossRef] [Green Version]
- Zhao, B.; Aggarwal, A.; Marshall, J.A.; Barletta, J.A.; Kijewski, M.F.; Lorch, J.H.; Nehs, M.A. Glycolytic inhibition with 3-bromopyruvate suppresses tumor growth and improves survival in a murine model of anaplastic thyroid cancer. Surgery 2022, 171, 227–234. [Google Scholar] [CrossRef] [PubMed]
- Tella, S.H.; Kommalapati, A.; Esquivel, M.A.; Correa, R. Potential Role of Metabolic Intervention in the Management of Advanced Differentiated Thyroid Cancer. Front. Oncol. 2017, 7, 160. [Google Scholar] [CrossRef] [Green Version]
- Li, Y.; Wei, W.; Shen, H.W.; Hu, W.Q. The study of inducing apoptosis effect of fructose 1,6-bisphosphate on the papillary thyroid carcinoma cell and its related mechanism. Tumour Biol. 2014, 35, 4539–4544. [Google Scholar] [CrossRef] [PubMed]
- Mussazhanova, Z.; Shimamura, M.; Kurashige, T.; Ito, M.; Nakashima, M.; Nagayama, Y. Causative role for defective expression of mitochondria-eating protein in accumulation of mitochondria in thyroid oncocytic cell tumors. Cancer Sci. 2020, 111, 2814–2823. [Google Scholar] [CrossRef] [PubMed]
- Nagayama, Y. Autophagy and thyroid cancer. J. Cancer Metastasis Treat. 2021, 7, 6. [Google Scholar] [CrossRef]
- Zhao, B.; Aggarwal, A.; Im, S.Y.; Viswanathan, K.; Landa, I.; Nehs, M.A. Effect of lactate export inhibition on anaplastic thyroid cancer growth and metabolism. J. Am. Coll. Surg. 2022, 234, 1044–1050. [Google Scholar] [CrossRef]
- Shiratori, R.; Furuichi, K.; Yamaguchi, M.; Miyazaki, N.; Aoki, H.; Chibana, H.; Ito, K.; Aoki, S. Glycolytic suppression dramatically changes the intracellular metabolic profile of multiple cancer cell lines in a mitochondrial metabolism-dependent manner. Sci. Rep. 2019, 9, 18699. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ma, L.; Cheng, Q. Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming. Biochem. Biophys. Res. Commun. 2018, 498, 912–917. [Google Scholar] [CrossRef]
- Lv, Z.; Yan, X.; Lu, L.; Su, C.; He, Y. Atovaquone enhances doxorubicin’s efficacy via inhibiting mitochondrial respiration and STAT3 in aggressive thyroid cancer. J. Bioenerg. Biomembr. 2018, 50, 263–270. [Google Scholar] [CrossRef]
- Wang, Y.; Xie, F.; Chen, D.; Wang, L. Inhibition of mitochondrial respiration by tigecycline selectively targets thyroid carcinoma and increases chemosensitivity. Clin. Exp. Pharmacol. Physiol. 2019, 46, 890–897. [Google Scholar] [CrossRef]
- Bikas, A.; Jensen, K.; Patel, A.; Costello, J.; Kaltsas, G.; Hoperia, V.; Wartofsky, L.; Burman, K.; Vasko, V. Mitotane induces mitochondrial membrane depolarization and apoptosis in thyroid cancer cells. Int. J. Oncol. 2019, 55, 7–20. [Google Scholar] [CrossRef] [PubMed]
- Buczyńska, A.; Sidorkiewicz, I.; Krętowski, A.J.; Zbucka-Krętowska, M.; Adamska, A. Metformin Intervention-A Panacea for Cancer Treatment? Cancers 2022, 14, 1336. [Google Scholar] [CrossRef] [PubMed]
- Chen, G.; Xu, S.; Renko, K.; Derwahl, M. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents. J. Clin. Endocrinol. Metab. 2012, 97, E510–E520. [Google Scholar] [CrossRef] [Green Version]
- Thakur, S.; Daley, B.; Gaskins, K.; Vasko, V.V.; Boufraqech, M.; Patel, D.; Sourbier, C.; Reece, J.; Cheng, S.Y.; Kebebew, E.; et al. Metformin targets mitochondrial glycerophosphate dehydrogenase to control rate of oxidative phosphorylation and growth of thyroid cancer in vitro and in vivo. Clin. Cancer Res. 2018, 24, 4030–4043. [Google Scholar] [CrossRef] [Green Version]
- Klubo-Gwiezdzinska, J.; Costello, J., Jr.; Patel, A.; Bauer, A.; Jensen, K.; Mete, M.; Burman, K.D.; Wartofsky, L.; Vasko, V. Treatment with metformin is associated with higher remission rate in diabetic patients with thyroid cancer. J. Clin. Endocrinol. Metab. 2013, 98, 3269–3279. [Google Scholar] [CrossRef] [Green Version]
- Bikas, A.; Jensen, K.; Patel, A.; Costello, J., Jr.; McDaniel, D.; Klubo-Gwiezdzinska, J.; Larin, O.; Hoperia, V.; Burman, K.D.; Boyle, L.; et al. Glucose-deprivation increases thyroid cancer cells sensitivity to metformin. Endocr. Realt. Cancer 2015, 22, 919–932. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Aggarwal, A.; Yuan, Z.; Barletta, J.A.; Lorch, J.H.; Nehs, M.A. Ketogenic diet combined with antioxidant N-acetylcysteine inhibits tumor growth in a mouse model of anaplastic thyroid cancer. Surgery 2020, 167, 87–93. [Google Scholar] [CrossRef] [PubMed]
- Yang, Z.; Huang, R.; Wei, X.; Yu, W.; Min, Z.; Ye, M. The SIRT6-autophagy-Warburg effect axis in papillary thyroid cancer. Front. Oncol. 2020, 10, 1265. [Google Scholar] [CrossRef] [PubMed]
- Liu, C.L.; Yang, P.S.; Wang, T.Y.; Huang, S.Y.; Kuo, Y.H.; Cheng, S.P. PGC1α downregulation and glycolytic phenotype in thyroid cancer. J. Cancer 2019, 10, 3819–3829. [Google Scholar] [CrossRef] [Green Version]
- Kim, H.M.; Koo, J.S. Differential expression of glycolysis-related proteins in follicular neoplasms versus Hürthle cell neoplasms: A retrospective analysis. Disease Markers 2017, 2017, 6230294. [Google Scholar] [CrossRef] [Green Version]
- Pathak, K.A.; Klonisch, T.; Nason, R.W.; Leslie, W.D. FDG-PET characteristics of Hürthle cell and follicular adenomas. Ann. Nucl. Med. 2016, 30, 506–509. [Google Scholar] [CrossRef] [PubMed]
- Zielke, A.; Tezelman, S.; Jossart, G.H.; Wong, M.; Siperstein, A.E.; Duh, Q.Y.; Clark, O.H. Establishment of a highly differentiated thyroid cancer cell line of Hurthle cell origin. Thyroid 1998, 8, 475–483. [Google Scholar] [CrossRef] [PubMed]
- Bonora, E.; Porcelli, A.M.; Gasparre, G.; Biondi, A.; Ghelli, A.; Carelli, V.; Baracca, A.; Tallini, G.; Martinuzzi, A.; Lenaz, G.; et al. Defective oxidative phosphorylation in thyroid oncocytic carcinoma is associated with pathogenic mitochondrial DNA mutations affecting complexes I and III. Cancer Res. 2006, 66, 6087–6096. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Porcelli, A.M.; Ghelli, A.; Iommarini, L.; Mariani, E.; Hoque, M.; Zanna, C.; Gasparre, G.; Rugolo, M. The antioxidant function of Bcl-2 preserves cytoskeletal stability of cells with defective respiratory complex I. Cell Mol. Life Sci. 2008, 65, 2943–2951. [Google Scholar] [CrossRef] [PubMed]
- Baris, O.; Savagner, F.; Nasser, V.; Loriod, B.; Granjeaud, S.; Guyetant, S.; Franc, B.; Rodien, P.; Rohmer, V.; Bertucci, F.; et al. Transcriptional profiling reveals coordinated up-regulation of oxidative metabolism genes in thyroid oncocytic tumors. J. Clin. Endocrinol. Metab. 2004, 89, 994–1005. [Google Scholar] [CrossRef] [Green Version]
- Addie, R.D.; Kostidis, S.; Corver, W.E.; Oosting, J.; Aminzadeh-Gohari, S.; Feichtinger, R.G.; Kofler, B.; Aydemirli, M.D.; Giera, M.; Morreau, H. Metabolic reprogramming related to whole-chromosome instability in models for Hürthle cell carcinoma. Sci. Rep. 2020, 10, 9578. [Google Scholar] [CrossRef]
- Kim, H.M.; Kim, E.S.; Koo, J.S. Differential expression of serine and glycine metabolism-related proteins between follicular neoplasm and Hürthle cell neoplasm. Int. J. Clin. Exp. Pathol. 2018, 11, 2064–2071. [Google Scholar]
- Porcelli, A.M.; Ghelli, A.; Ceccarelli, C.; Lang, M.; Cenacchi, G.; Capristo, M.; Pennisi, L.F.; Morra, I.; Ciccarelli, E.; Melcarne, A.; et al. The genetic and metabolic signature of oncocytic transformation implicates HIF1alpha destabilization. Hum. Mol. Genet. 2010, 19, 1019–1032. [Google Scholar] [CrossRef] [Green Version]
- Gasparre, G.; Hervouet, E.; de Laplanche, E.; Demont, J.; Pennisi, L.F.; Colombel, M.; Mège-Lechevallier, F.; Scoazec, J.Y.; Bonora, E.; Smeets, R.; et al. Clonal expansion of mutated mitochondrial DNA is associated with tumor formation and complex I deficiency in the benign renal oncocytoma. Hum. Mol. Genet. 2008, 17, 986–995. [Google Scholar] [CrossRef] [Green Version]
- Sharma, L.K.; Fang, H.; Liu, J.; Vartak, R.; Deng, J.; Bai, Y. Mitochondrial respiratory complex I dysfunction promotes tumorigenesis through ROS alteration and AKT activation. Hum. Mol. Genet. 2011, 20, 4605–4616. [Google Scholar] [CrossRef] [Green Version]
- Kürschner, G.; Zhang, Q.; Clima, R.; Xiao, Y.; Busch, J.F.; Kilic, E.; Jung, K.; Berndt, N.; Bulik, S.; Holzhütter, H.G.; et al. Renal oncocytoma characterized by the defective complex I of the respiratory chain boosts the synthesis of the ROS scavenger glutathione. Oncotarget 2017, 8, 105882–105904. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Feng, J.; Zhang, Q.; Li, C.; Zhou, Y.; Zhao, S.; Hong, L.; Song, Q.; Yu, S.; Hu, C.; Wang, H.; et al. Enhancement of mitochondrial biogenesis and paradoxical inhibition of lactate dehydrogenase mediated by 14-3-3η in oncocytomas. J. Pathol. 2018, 245, 361–372. [Google Scholar] [CrossRef] [PubMed]
- Saito, Y.; Soga, T. Amino acid transporters as emerging therapeutic targets in cancer. Cancer Sci. 2021, 112, 2958–2965. [Google Scholar] [CrossRef] [PubMed]
- Coelho, M.; Raposo, L.; Goodfellow, B.J.; Atzori, L.; Jones, J.; Manadas, B. The potential of metabolomics in the diagnosis of thyroid cancer. Int. J. Mol. Sci. 2020, 21, 5272. [Google Scholar] [CrossRef]
- Shen, L.; Qian, C.; Cao, H.; Wang, Z.; Luo, T.; Liang, C. Upregulation of the solute carrier family 7 genes is indicative of poor prognosis in papillary thyroid carcinoma. World J. Surg. Oncol. 2018, 16, 235. [Google Scholar] [CrossRef] [Green Version]
- Häfliger, P.; Graff, J.; Rubin, M.; Stooss, A.; Dettmer, M.S.; Altmann, K.H.; Gertsch, J.; Charles, R.P. The LAT1 inhibitor JPH203 reduces growth of thyroid carcinoma in a fully immunocompetent mouse model. J. Exp. Clin. Cancer Res. 2018, 37, 234. [Google Scholar] [CrossRef]
- Enomoto, K.; Sato, F.; Tamagawa, S.; Gunduz, M.; Onoda, N.; Uchino, S.; Muragaki, Y.; Hotomi, M. A novel therapeutic approach for anaplastic thyroid cancer through inhibition of LAT1. Sci. Rep. 2019, 9, 14616. [Google Scholar] [CrossRef] [Green Version]
- Ducker, G.S.; Rabinowitz, J.D. One-carbon metabolism in health and disease. Cell Metab. 2017, 25, 27–42. [Google Scholar] [CrossRef] [Green Version]
- Sun, W.Y.; Kim, H.M.; Jung, W.H.; Koo, J.S. Expression of serine/glycine metabolism-related proteins is different according to the thyroid cancer subtype. J. Transl. Med. 2016, 14, 168. [Google Scholar] [CrossRef] [Green Version]
- Jeon, M.J.; You, M.H.; Han, J.M.; Sim, S.; Yoo, H.J.; Lee, W.K.; Kim, T.Y.; Song, D.E.; Shong, Y.K.; Kim, W.G.; et al. High phosphoglycerate dehydrogenase expression induces stemness and aggressiveness in thyroid cancer. Thyroid 2020, 30, 1625–1638. [Google Scholar] [CrossRef]
- DeBerardinis, R.J.; Mancuso, A.; Daikhin, E.; Nissim, I.; Yudkoff, M.; Wehrli, S.; Thompson, C.B. Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc. Nat. Acad. Sci. USA 2007, 104, 19345–19350. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Scott, D.A.; Richardson, A.D.; Filipp, F.V.; Knutzen, C.A.; Chiang, G.G.; Ronai, Z.A.; Osterman, A.L.; Smith, J.W. Comparative metabolic flux profiling of melanoma cell lines: Beyond the Warburg effect. J. Biol. Chem. 2011, 286, 42626–42634. [Google Scholar] [CrossRef] [PubMed]
- Chen, Q.; Kirk, K.; Shurubor, Y.I.; Zhao, D.; Arreguin, A.J.; Shahi, I.; Valsecchi, F.; Primiano, G.; Calder, E.L.; Carelli, V.; et al. Rewiring of glutamine metabolism is a bioenergetic adaptation of human cells with mitochondrial DNA mutations. Cell Metab. 2018, 27, 1007–1025.e1005. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mullen, A.R.; Wheaton, W.W.; Jin, E.S.; Chen, P.H.; Sullivan, L.B.; Cheng, T.; Yang, Y.; Linehan, W.M.; Chandel, N.S.; DeBerardinis, R.J. Reductive carboxylation supports growth in tumour cells with defective mitochondria. Nature 2012, 481, 385–388. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kodama, M.; Oshikawa, K.; Shimizu, H.; Yoshioka, S.; Takahashi, M.; Izumi, Y.; Bamba, T.; Tateishi, C.; Tomonaga, T.; Matsumoto, M.; et al. A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer. Nat. Commun. 2020, 11, 1320. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kim, H.M.; Lee, Y.K.; Koo, J.S. Expression of glutamine metabolism-related proteins in thyroid cancer. Oncotarget 2016, 7, 53628–53641. [Google Scholar] [CrossRef] [Green Version]
- Cha, Y.J.; Jang, H.; Koo, J.S. Expression of glutamine metabolism-related proteins in Hürthle cell neoplasm of thyroid: Comparison with follicular neoplasm. Histol. Histopathol. 2019, 34, 167–174. [Google Scholar] [CrossRef]
- Yu, Y.; Yu, X.; Fan, C.; Wang, H.; Wang, R.; Feng, C.; Guan, H. Targeting glutaminase-mediated glutamine dependence in papillary thyroid cancer. J. Mol. Med. 2018, 96, 777–790. [Google Scholar] [CrossRef]
- Uddin, S.; Siraj, A.K.; Al-Rasheed, M.; Ahmed, M.; Bu, R.; Myers, J.N.; Al-Nuaim, A.; Al-Sobhi, S.; Al-Dayel, F.; Bavi, P.; et al. Fatty acid synthase and AKT pathway signaling in a subset of papillary thyroid cancers. J. Clin. Endocrinol. Metab. 2008, 93, 4088–4097. [Google Scholar] [CrossRef] [Green Version]
- Liu, J.; Brown, R.E. Immunohistochemical expressions of fatty acid synthase and phosphorylated c-Met in thyroid carcinomas of follicular origin. Int. J. Clin. Exp. Pathol. 2011, 4, 755–764. [Google Scholar]
- Guo, S.; Qiu, L.; Wang, Y.; Qin, X.; Liu, H.; He, M.; Zhang, Y.; Li, Z.; Chen, X. Tissue imaging and serum lipidomic profiling for screening potential biomarkers of thyroid tumors by matrix-assisted laser desorption/ionization-Fourier transform ion cyclotron resonance mass spectrometry. Anal. Bioanal. Chem. 2014, 406, 4357–4370. [Google Scholar] [CrossRef] [PubMed]
- Sena, L.A.; Denmeade, S.R. Fatty acid synthesis in prostate cancer: Vulnerability or epiphenomenon? Cancer Res. 2021, 81, 4385–4393. [Google Scholar] [CrossRef] [PubMed]
- Li, C.; Peng, X.; Lv, J.; Zou, H.; Liu, J.; Zhang, K.; Li, Z. SREBP1 as a potential biomarker predicts levothyroxine efficacy of differentiated thyroid cancer. Biomed. Pharmacother. 2020, 123, 109791. [Google Scholar] [CrossRef] [PubMed]
- von Roemeling, C.A.; Marlow, L.A.; Pinkerton, A.B.; Crist, A.; Miller, J.; Tun, H.W.; Smallridge, R.C.; Copland, J.A. Aberrant lipid metabolism in anaplastic thyroid carcinoma reveals stearoyl CoA desaturase 1 as a novel therapeutic target. J. Clin. Endocrinol. Metab. 2015, 100, E697–E709. [Google Scholar] [CrossRef] [PubMed]
- Valvo, V.; Iesato, A.; Kavanagh, T.R.; Priolo, C.; Zsengeller, Z.; Pontecorvi, A.; Stillman, I.E.; Burke, S.D.; Liu, X.; Nucera, C. Fine-tuning lipid metabolism by targeting mitochondria-associated acetyl-CoA-carboxylase 2 in BRAF(V600E) papillary thyroid carcinoma. Thyroid 2021, 31, 1335–1358. [Google Scholar] [CrossRef]
- Lu, J.; Zhang, Y.; Sun, M.; Ding, C.; Zhang, L.; Kong, Y.; Cai, M.; Miccoli, P.; Ma, C.; Yue, X. Multi-omics analysis of fatty acid metabolism in thyroid carcinoma. Front. Oncol. 2021, 11, 737127. [Google Scholar] [CrossRef]
- Leng, J.; Guan, Q.; Sun, T.; Wu, Y.; Cao, Y.; Guo, Y. Application of isotope-based carboxy group derivatization in LC-MS/MS analysis of tissue free-fatty acids for thyroid carcinoma. J. Pharm. Biomed. Anal. 2013, 84, 256–262. [Google Scholar] [CrossRef]
- Miccoli, P.; Torregrossa, L.; Shintu, L.; Magalhaes, A.; Chandran, J.; Tintaru, A.; Ugolini, C.; Minuto, M.N.; Miccoli, M.; Basolo, F.; et al. Metabolomics approach to thyroid nodules: A high-resolution magic-angle spinning nuclear magnetic resonance-based study. Surgery 2012, 152, 1118–1124. [Google Scholar] [CrossRef]
- Wojakowska, A.; Cole, L.M.; Chekan, M.; Bednarczyk, K.; Maksymiak, M.; Oczko-Wojciechowska, M.; Jarząb, B.; Clench, M.R.; Polańska, J.; Pietrowska, M.; et al. Discrimination of papillary thyroid cancer from non-cancerous thyroid tissue based on lipid profiling by mass spectrometry imaging. Endokrynol. Pol. 2018, 69, 2–8. [Google Scholar] [CrossRef] [Green Version]
- Ishikawa, S.; Tateya, I.; Hayasaka, T.; Masaki, N.; Takizawa, Y.; Ohno, S.; Kojima, T.; Kitani, Y.; Kitamura, M.; Hirano, S.; et al. Increased expression of phosphatidylcholine (16:0/18:1) and (16:0/18:2) in thyroid papillary cancer. PLoS ONE 2012, 7, e48873. [Google Scholar] [CrossRef] [Green Version]
- Li, J.; Eu, J.Q.; Kong, L.R.; Wang, L.; Lim, Y.C.; Goh, B.C.; Wong, A.L.A. Targeting metabolism in cancer cells and the tumour microenvironment for cancer therapy. Molecules 2020, 25, 4831. [Google Scholar] [CrossRef] [PubMed]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Nagayama, Y.; Hamada, K. Reprogramming of Cellular Metabolism and Its Therapeutic Applications in Thyroid Cancer. Metabolites 2022, 12, 1214. https://doi.org/10.3390/metabo12121214
Nagayama Y, Hamada K. Reprogramming of Cellular Metabolism and Its Therapeutic Applications in Thyroid Cancer. Metabolites. 2022; 12(12):1214. https://doi.org/10.3390/metabo12121214
Chicago/Turabian StyleNagayama, Yuji, and Koichiro Hamada. 2022. "Reprogramming of Cellular Metabolism and Its Therapeutic Applications in Thyroid Cancer" Metabolites 12, no. 12: 1214. https://doi.org/10.3390/metabo12121214